In "The Next Five Years in Psoriasis: Remission, Access, and Combinations," the panel looks ahead to the advances and the unfinished work of the coming years. Dr. Han hopes the field will embrace all components of psoriatic disease equally and reach consensus on remission for the joints, not just the skin. He points out that even very low disease activity still allows up to one joint, so the definitions themselves show how far the joint side has to go.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Grace Wright
The Patient Who Is Better but Not Clear: Shared Decisions in Psoriasis
"The Patient Who Is Better but Not Clear: Shared Decisions in Psoriasis" takes up the common scenario of a patient content with partial improvement. Dr. Han says fear of the unknown is powerful. A patient who remembers how bad things were feels better and hesitates to switch. It is the devil they know versus the one they don't. They wonder whether a new medicine will truly be better or carry some side effect, and they have grown used to their current injection.
Putting On-Treatment Remission Into Practice: A Patient-Defined Target in Psoriasis
In "Putting On-Treatment Remission Into Practice: A Patient-Defined Target in Psoriasis," the panel returns to remission and grounds it in what patients actually live with. Dr. Han starts by qualifying the 0% BSA goal. Clear skin with swollen, painful joints is not remission by any human standard. He frames the real target as a life free of psoriatic disease, where a patient functions normally and does not have to think about it.
Real-World Evidence and Systemic Inflammation in Psoriasis
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 10 Published on: , , In "Real-World Evidence and Systemic Inflammation in Psoriasis," our experts scrutinize the evidence behind popular claims about disease progression. In "Real-World Evidence and Systemic Inflammation in Psoriasis," our experts scrutinize the evidence behind popular claims about disease progression.
IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 9 Published on: , , This episode, "IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health," features the panel putting the class's safety signals in context. This episode, "IL-17 Inhibitor Safety in Psoriasis: Candidiasis, IBD, and Mental Health," features the panel putting the class's safety signals in context. Dr. Wright says candidiasis does not trouble her.
BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 8 Published on: , , In "BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA," the panel digs into the trial that broke the usual non-inferiority pattern. In "BE BOLD Head-to-Head: IL-17 vs IL-23 for Psoriasis and PsA," the panel digs into the trial that broke the usual non-inferiority pattern.
Exploring the IL-17 vs IL-23 Debate in Psoriasis
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 7 Published on: , , "Exploring the IL-17 vs IL-23 Debate in Psoriasis " takes up a deliberately provocative question from the moderator. "Exploring the IL-17 vs IL-23 Debate in Psoriasis " takes up a deliberately provocative question from the moderator. Dr. Wright says the answer is complicated.
L-17 vs IL-23: Head-to-Head Data in Psoriasis and PsA
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 6 Published on: , , In "IL-17 vs IL-23: Head-to-Head Data in Psoriasis and PsA," our experts turn to the trials clinicians actually reach for when choosing a class. In "IL-17 vs IL-23: Head-to-Head Data in Psoriasis and PsA," our experts turn to the trials clinicians actually reach for when choosing a class.
Targeting the Pathways: TNF, IL-17, and IL-23 in Psoriasis
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 5 Published on: , , This episode, "Targeting the Pathways: TNF, IL-17, and IL-23 in Psoriasis," features the panel unpacking the biology behind today's biologics. This episode, "Targeting the Pathways: TNF, IL-17, and IL-23 in Psoriasis," features the panel unpacking the biology behind today's biologics.
Defining On-Treatment Remission in Psoriasis and PsA
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 4 Published on: , , In "Defining On-Treatment Remission in Psoriasis and PsA," the panel examines whether clear should now mean completely clear. In "Defining On-Treatment Remission in Psoriasis and PsA," the panel examines whether clear should now mean completely clear. Dr. Han recounts his work with the National Psoriasis Foundation and its earlier treat-to-target guidelines.
Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 3 Published on: , , "Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care" takes up the question of how two specialties can stop working in isolation. "Breaking Down Silos: Rheum-Derm Collaboration in Psoriasis Care" takes up the question of how two specialties can stop working in isolation. Dr. Han describes how lucky he was early in his career to sit next door to rheumatology.
Screening Psoriasis Patients for Early Psoriatic Arthritis
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 2 Published on: , , Most psoriatic arthritis is preceded by psoriasis, which puts dermatologists on the front line of early detection. The panel details which patients warrant a closer look and how to screen efficiently. This episode, "Screening Psoriasis Patients for Early Psoriatic Arthritis," turns to what a dermatologist should ask and look for when psoriasis walks through the door.
Where Psoriasis and PsA Care Stand Today: Burden and Unmet Needs
Elevating Psoriasis Care: The Role of IL-17 Inhibition in Advancing On-Treatment Remission - Episode 1 Published on: , , Plaque psoriasis has reached total clearance for many patients, yet psoriatic arthritis still lags behind. The panel opens by mapping where the two halves of psoriatic disease diverge. Welcome back to another HCPLive Peer Exchange series.
A 20-year reflection on women in rheumatology - Nature Reviews Rheumatology
The collective priorities of the rheumatology field represent the lived experience, and therefore diversity of its members. The ‘mould’ of rheumatology, that is, its culture, structures and expectations, was not created for or by women, but women have slowly changed this mould to make space for diverse perspectives.
US Health Care Disparities in Immunology Biologics Access: A Systematic Review
Objectives: Biologics have substantially improved health outcomes for patients with immunologic conditions. However, not all patients have equitable access to these important medications. Accordingly, we conducted a systematic review to understand US health care disparities in biologics access and associated clinical and economic outcomes, including health care resource use, across immunology (ie, rheumatology, gastroenterology, and dermatology). Study Design: Systematic literature review.
Closing Remarks
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 16 Published on: , , , , Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes. Video content above is prompted by the following: Can each of you provide closing remarks on how you treat your own patients to achieve remission?
Safety and Efficacy of Janus Kinase Inhibitors
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 15 Published on: , , , , Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.
Cycling Within TNF Inhibitors: Complications and Factors Influencing Treatment Choices
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 14 Published on: , , , , Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for...
Outcomes of Class Switching vs Cycling TNF Inhibitors
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 13 Published on: , , , , Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.
JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 11 Published on: , , , , Panelists discuss how JAK inhibitors and TNF inhibitors differ in administration, efficacy, and safety due to their unique characteristics and mechanisms of action, with further variations in binding activities within the TNFi class impacting clinical outcomes.
JAK Inhibitor Selectivity and Dose-Related Toxicity
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 12 Published on: , , , , Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.
Advanced Treatment Options for RA: Exploring the Data
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 9 Published on: , , , , Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).
Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 10 Published on: , , , , Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies. Video content above is prompted by the following: How do head-to-head data affect your treatment decisions?
Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 8 Published on: , , , , Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.
Achieving Low Disease Activity and Remission: Managing Patient Expectations
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 7 Published on: , , , , Experts discuss strategies for achieving low disease activity or remission in patients, including steps taken in clinical practice and methods for managing patient expectations regarding treatment outcomes. Video content above is prompted by the following: In your practice, what steps do you take to ensure your patients reach low disease activity, and/or remission?
Health Disparities in Rheumatology: A Literature Review
Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 17 Authors Wright GC, Zueger PM, Copley-Merriman C, Khan S, Costello J, Krumbach A, Reddy P, Tanjinatus O, Wells AF Received 28 August 2024 Accepted for publication 27 November 2024 Published 9 January 2025 Volume 2025:17 Pages 1—12 DOI https://doi.org/10.2147/OARRR.S493457 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Chuan-Ju Liu...
Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 5 Published on: , , , , A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.
Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 6 Published on: , , , , Medical experts explore how patient perceptions of rheumatoid arthritis can differ from disease activity assessments and provide an example of hidden symptoms revealed through further probing, along with the impact of therapy adjustments on achieving remission.
Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 3 Published on: , , , , A panel of medical experts discuss the prevalence and management of poorly controlled rheumatoid arthritis in clinical practice. Video content above is prompted by the following: As we know, many patients do not reach clinical remission and experience uncontrolled disease and progression. In your practice, how frequently do you see poorly controlled rheumatoid arthritis?
Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 3 Published on: , , , , A panel of medical experts discuss how clinical guidelines currently define clinical remission, as well as the clinical and economic benefits associated with clinical remission. Over the past few years, the goal of rheumatoid arthritis treatment has evolved from relieving symptoms to achieving clinical remission, which inhibits radiologic damage and prevents disability. 1.
Intro and Welcomes
Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 2 Intro and Welcomes Published on: August 8, 2024 Gordon Lam, MD, Leonard Calabrese, DO, Grace Wright, MD, PhD, Jeffrey A. Sparks, MD, MMSc, Catherine Bakewell, MD A panel of medical experts introduce themselves before diving into a discussion about remission achievement in rheumatoid arthritis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Grace
Contact Grace, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack